ABOUT SIMR
Company Profile
Management Team
SAB
Vision & Mission
Milestones
Investors
R&D
Research Field
Pipeline
Translational Center
MEDIA
Expanded Access Policy
Press Releases
PARTNER
Business Development
Research Cooperation
JOIN US
CONTACT
中文
|
EN
ABOUT SIMR
Company Profile
Management Team
SAB
Vision & Mission
Milestones
Investors
R&D
Research Field
Pipeline
Translational Center
MEDIA
Expanded Access Policy
Press Releases
PARTNER
Business Development
Research Cooperation
JOIN US
CONTACT
中文
EN
Expanded Access Policy
Press Releases
Home
>
MEDIA
>
Press Releases
Press Releases
Expanded Access Policy
Press Releases
16
2024-09
First Patient Enrolled in Phase 2 Clinical Trial of SR750 fo
Shanghai, China – [September 16th, 2024] – SIMR Biotech announces the enrollment...
11
2024-09
First Patient Enrolled in Phase 2 Clinical Trial of SR1375 i
On 11th September 2024, Shanghai SIMR Biotechnology Co., Ltd. announced that the...
03
2023-01
Milestone - SR1375'S Phase II Clinical Trial Approved by th
On December 13, 2022,Shanghai SIMR Biotechnology Co., Ltd announced that, the candidate drug SR1375 with a new mechanism of action for the treatment of acute inflammation solely developed by the compa...
12
2022-11
Shanghai SIMR Biotech received 150 million Chinese Yuan C1 r
On November 8, 2022, Shanghai SIMR Biotech (here in after referred to as "SIMR Bio " or the "Company") announced that it has obtained a C1 round of financing of 150 million Chinese...
17
2021-12
Milestone of SIMR —— The first Phase II clinical study for S
On 17th Dec 2021, Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company”) announced that company’s investigational drug SR419, the first asset of SIMR e...
01
2021-11
Milestone - SR1375'S Phase II Clinical Trial Approved by the
Shanghai, China, Nov 1,2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company") initiated the first-in-human study of candidate drug SR750...
Home
Previous
1
2
3
Next
Last
Previous
Next
Road
3
page
15
strip